BNGO
Bionano Genomics, Inc.
Key Financials
Revenue
$28.5M
↓ 7.4%
Operating Income
$-33339000
↑ 67.9%
EPS (Diluted)
$-4.85
↑ 94.5%
Net Income
$-26395000
↑ 76.4%
Shareholders' Equity
$44.4M
↑ 25.6%
Total Assets
$73.6M
↓ 4.0%
Total Liabilities
$29.2M
↓ 29.4%
Cash & Equivalents
$3.0M
↓ 67.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/14/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 8/21/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BNGO |
| Company Name | Bionano Genomics, Inc. |
| CIK | 1411690 |
| Sector | Laboratory Analytical Instruments |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 3826 |
| SIC Description | Laboratory Analytical Instruments |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 888-7600 |